Showing 1801-1810 of 2652 results for "".
- Moderna Gives First Vaccine Shots To Young Kids As Part Of COVID-19 Studyhttps://modernod.com/news/moderna-gives-first-vaccine-shots-to-young-kids-as-part-of-covid-19-study/2478978/Children have now received their first doses of Moderna’s COVID-19 vaccine, as the company studies the safety and effectiveness of the vaccine for kids ages 6 months to less than 12 years old, according to an NPR
- Hydrus Microstent Now First MIGS Device With 5-Year Pivotal Trial Datahttps://modernod.com/news/hydrus-microstent-now-first-migs-device-with-5-year-pivotal-trial-data/2478937/Ivantis, developer of the novel Hydrus Microstent, announced the first release of 5-year follow-up data from its HORIZON pivotal trial. This milestone represents the longest continuous follow-up of a MIGS device pivotal trial. The 5-year HORIZON data demonstrated the Hydrus Microstent̵
- Single Dose of Pfizer, BioNTech’s COVID-19 Vaccine 85% Effective: Studyhttps://modernod.com/news/single-dose-of-pfizer-biontechs-covid-19-vaccine-85-effective-study/2478893/Study results published in The Lancet showed that a single dose of Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 is 85% effective at preventing symptomatic disease 15 to 28 days after being administered. The data, which come from an analysis of healthcare workers in Israel, also
- Kodiak Sciences Announces 1-Year Data from Ongoing Phase 1b Study of KSI-301 in Patients with Retinal Vascular Diseaseshttps://modernod.com/news/kodiak-sciences-announces-1-year-data-from-ongoing-phase-1b-study-of-ksi-301-in-patients-with-retinal-vascular-diseases/2478877/Kodiak Sciences announced promising 1-year durability, efficacy and safety data from the ongoing phase 1b study of its investigational therapy KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular d
- Johnson & Johnson Vision Celebrates 20 Years of See More Campaign and Global Patient Story Searchhttps://modernod.com/news/johnson-johnson-vision-celebrates-20-years-of-see-more-campaign-and-global-patient-story-search/2478846/Johnson & Johnson Vision announced a month-long celebration of the 20th Anniversary of the Tecnis platform, the proprietary combination of materials and design on which Johnson & Johnson Vision IOLs are built. Twenty years ago, a team of researchers and innovators created Tecnis, setting
- Prevent Blindness and Bausch + Lomb to Launch Year-Long Video Series to Raise Awareness of Wet AMDhttps://modernod.com/news/prevent-blindness-and-bausch-lomb-to-launch-year-long-video-series-to-raise-awareness-of-wet-amd/2478818/Bausch + Lomb and Prevent Blindness, the nation’s oldest volunteer eye health non-profit organization, announced they are joining together for the sixth consecutive year during AMD Awareness Month to raise awareness of age-related macular degeneration (AMD). The two organizations will launch a ye
- J&J’s Single-Dose COVID-19 Vaccine 66% Effectivehttps://modernod.com/news/jjs-single-dose-covid-19-vaccine-66-effective/2478814/Johnson & Johnson reported topline results Friday showing that its investigational single-dose vaccine candidate Ad26.COV2.S met all primary and key secondary endpoints of the phase 3 ENSEMBLE study, with an overall efficacy rate of 66% at preventing moderate-to-severe COVID-19, 28 days after
- Elizabeth Yeu, MD, and K. Peony Yu, MD, Appointed to Staar Surgical Board of Directorshttps://modernod.com/news/elizabeth-yeu-md-and-k-peony-yu-md-appointed-to-staar-surgical-board-of-directors/2478798/Staar Surgical announced the appointments of Elizabeth Yeu, MD, Partner, Virginia Eye Consultants, and K. Peony Yu, MD, retired Chief Medical Officer, FibroGen, to its Board of Directors, effective January 21, 2021. “The addition of Dr. Elizabeth Yeu and Dr. K. Peony Yu to our Board of Dir
- Vision Innovation Partners Completes 17th Acquisition, Eyes of Yorkhttps://modernod.com/news/vision-innovation-partners-completes-17th-acquisition-eyes-of-york/2478708/Vision Innovation Partners announced that it has acquired Eyes of York, an ophthalmology practice in York, Pennsylvania. The acquisition strengthens Vision Innovation Partners’ presence in the
- Fewer New Cases of Intraocular Inflammation After First Year of Abicipar in AMD Patientshttps://modernod.com/news/fewer-new-cases-of-intraocular-inflammation-after-first-year-of-abicipar-in-amd-patients/2478703/Most cases of intraocular inflammation in patients with neovascular age-related macular degeneration (nAMD) who take AbbVie’s investigational drug abicipar pegol develop during the first year of treatment, according to a new report of two-year efficacy and safety results from a couple of pi